Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Phosphatidylinositol
100%
Antiproliferative Activity
100%
Carcinoma Cell Lines
100%
Mammalian Target of Rapamycin Pathway
100%
Cyclin-dependent Kinase 4 (CDK4)
100%
Squamous Carcinoma Cells
100%
AKT/mammalian Target of Rapamycin
100%
PI3Ki
83%
Apoptosis
50%
Cell Viability
33%
Glycolytic Metabolism
33%
Oxidative Metabolism
33%
Cell Cycle Arrest
33%
Cyclin D1 (CCND1)
33%
Tumor
16%
Induced Apoptosis
16%
Retinoblastoma
16%
Therapeutic Agents
16%
Flow Cytometry
16%
Receptor Tyrosine Kinase
16%
Cellular Metabolism
16%
Pathway Activity
16%
Western Blot Analysis
16%
Metabolic Changes
16%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
16%
Pathway Inhibitors
16%
MTT Assay
16%
Buparlisib
16%
Life Cycle Analysis
16%
Alpelisib
16%
Extracellular Flux Analysis
16%
PI3KCA
16%
Ribociclib
16%
Annexin V Staining
16%
Cyclin-dependent Kinase 6 (CDK6)
16%
Suppressing Cell
16%
Seahorse XF96
16%
Gedatolisib
16%
CDK4/6 Inhibitor Palbociclib
16%
Protein Inactivation
16%
P16 Protein
16%
Medicine and Dentistry
Wart Virus
100%
Mechanistic Target of Rapamycin
100%
Antiproliferative Activity
100%
Phosphatidylinositol
100%
Head and Neck Squamous Cell Carcinoma Cell Line
100%
Protein Kinase B
100%
CDK4/6 Inhibitor
100%
Programmed Cell Death
80%
Head and Neck Squamous Cell Carcinoma
60%
In Vitro
40%
Cell Line
40%
Cell Viability
40%
Cell Cycle Checkpoint
40%
Cell Cycle Arrest
40%
Western Blot
20%
Neoplasm
20%
Therapeutic Agent
20%
Phosphotransferase
20%
Flow Cytometry
20%
Aerobic Metabolism
20%
Lipocortin 5
20%
Cell Metabolism
20%
Protein Tyrosine Kinase
20%
Retinoblastoma
20%
Cyclin D1
20%
Cyclin Dependent Kinase Inhibitor 2A
20%
MTT Assay
20%
Squamous Cell Carcinoma Cell
20%
Buparlisib
20%
Alpelisib
20%
Ribociclib
20%
Cell-Cycle Analysis
20%
Palbociclib
20%
Protein P16
20%
Gedatolisib
20%
Immunology and Microbiology
Sirolimus
100%
Antiproliferative Activity
100%
Wart Virus
100%
Head and Neck Squamous Cell Carcinoma Cell Line
100%
Programmed Cell Death
100%
Neck
75%
Cell Line
50%
Cell Cycle Checkpoint
50%
Squamous Cell
50%
Cell Cycle Arrest
50%
Cell Viability
50%
Western Blot
25%
Cell Cycle
25%
Aerobic Metabolism
25%
Cell Metabolism
25%
Cyclin D1
25%
Squamous Cell Carcinoma Cell
25%
Seahorse
25%
Extracellular Flux
25%
Tyrosine
25%
INIS
humans
100%
carcinomas
100%
apoptosis
66%
metabolism
50%
viability
50%
cell cycle
50%
proteins
33%
kinases
33%
in vitro
33%
oxidation
33%
amplification
33%
patients
16%
tumors
16%
receptors
16%
losses
16%
mutations
16%
tyrosine
16%
therapeutic agents
16%
blocking
16%
inactivation
16%
glycolysis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Human Papillomavirus
100%
Mammalian Target of Rapamycin
100%
Head and Neck Squamous Cell Carcinoma
100%
Phosphatidylinositol
100%
Cell Viability
33%
Neoplasm
16%
Western Blot
16%
Flow Cytometry
16%
Protein Tyrosine Kinase
16%
Lipocortin 5
16%
Cyclin Dependent Kinase 4
16%
Cyclin D1
16%
Cyclin Dependent Kinase Inhibitor 2A
16%
Buparlisib
16%
Alpelisib
16%
Retinoblastoma
16%
Seahorse
16%
Ribociclib
16%
Palbociclib
16%
Protein P16
16%
Gedatolisib
16%